Replies to post #51774 on RespireRx Pharmaceuticals Inc (fka RSPI)

[bigtalan]

With that information feeling good about the shares I am holding.

[meixatech]

There is also the anti-cancer ampakine. "results demonstrated for the first time that concentrations of the Class I ampakine CX614, which increase AMPAR agonist binding affinity, possess oncolytic activity as a sole agent and synergistically reduce GBM viability when paired with FLX. FLX also demonstrates a dose-dependent induction of apoptosis in cancer cells originating outside the CNS that overexpress calcium-permeable AMPARs. Likewise, CX614 inhibits cancer cell viability in a dose-dependent fashion and its combination with FLX synergistically reduces cell viability. These effects of CX614 were not seen with the Class II ampakines, CX717 and CX1739." This also can be huge.

[crazy horse 0]

QUOTE It could get very interesting into EOY and certainly in 2025. Hard to really think of this as an OTC stock. The pipeline is representitive of a mid major pharma trading on the nasdaq. Being on the EM with zero otc liquidity adds to that flavor. Heavy equity related investment by insiders, only sophisticated and institutional can really acquire now on the EM, those longs who have held have significantly tightened the share supply. Kinda like a "private" company waiting to IPO.... No reason to give away shares for peanuts... GLTA

Absolutely. When you invest and conduct due diligence (essentially a true long position) the more information you gather and continue to gather helps paint that picture you need.

Clearly there has been a plan in place for some time as to accomplishing financing and finishing up these filings alongside a vision of how that will unfold. It will be interesting now that this is on the EM, how this will respond to filings starting to hit in the future and further updates. Unless they drop all the filings at once and are off the EM in a few days after, but sounds like this all could be a process and could test the nature of the EM market as sophisticated investors would want a piece of the pie given the following..

Given the backdrop of a key phase 2 trial upcoming for SCI funded by the DOD and this likely leads into ADHD trials ALONG WITH grant funding likely early in 2025 for getting KRM-ll-81 into epilepsy human clinicals... well this is BIG. Either platform individually into human clinicals is a huge pharma deal, but combined wow! There is no doubt money is at the door now, these are two huge opportunities and is a no brainer. At this point the question likely becomes structure. Will they spin out either or both platforms as part of whatever financing is in the works?? IF so, will that be done before or after leaving the EM?

It could get very interesting into EOY and certainly in 2025. Hard to really think of this as an OTC stock. The pipeline is representitive of a mid major pharma trading on the nasdaq. Being on the EM with zero otc liquidity adds to that flavor. Heavy equity related investment by insiders, only sophisticated and institutional can really acquire now on the EM, those longs who have held have significantly tightened the share supply. Kinda like a "private" company waiting to IPO.... No reason to give away shares for peanuts... GLTA